THERACAST
We map how drugs — and aging — change the whole brain. We use those maps to build next-generation treatments.
Mapping drug-induced brain effects — brain-wide, drug by drug.
Theracast's discovery platform detects hundreds of thousands of c-Fos+ cells across the whole mouse brain, turning every drug into a functional whole-brain signature. AI-aided comparison across 250+ mapped compounds isolates the circuit patterns that track clinical efficacy — and the ones that track side effects.
01Dose
Administer a drug candidate in mice.
02Map
Detect hundreds of thousands of c-Fos+ cells across the whole brain — a marker of neuronal activation.
03Compare
Run statistical comparisons across drugs, doses, and treatment regimens.
04Signature
Produce a functional whole-brain profile for every drug.
Platform methodology published in Cell: Renier et al., 2016 · Kim et al., 2017. Mapped signatures have accurately predicted the outcomes of historical and recent clinical trials.
Mapping how the brain ages.
Beyond psychiatry: whole-brain mapping in young and aged mice shows aging systematically redistributing brain activity across 657 regions — a quantitative assay for aging and intervention studies.
Depression care is slow — and the fast option comes with baggage.
Ketamine and esketamine proved that antidepressant action within hours is possible, but dissociation and in-clinic dosing keep them out of reach for most patients. Theracast's lead combination is built for ketamine-like speed — without the baggage, as a simple at-home oral treatment.
Two programs built on the platform.
Both programs combine approved generics identified by whole-brain mapping — de-risked components, novel mechanisms, protected by a method-of-treatment patent filed in 2024.
A safe, rapid-acting, efficacious treatment built on a novel combination mechanism.
Engages both antidepressant-linked brain circuits from the first dose — engineered for rapid action without ketamine-like side effects.
CLINIC-READY · PHASE 1b IN 2027A safe, efficacious treatment built on a novel combination mechanism.
An innovative, highly effective schizophrenia treatment following the same platform-driven combination playbook.
PRECLINICALFounders with decades at the top of neuroscience and psychiatry.
Pavel Osten, M.D., Ph.D.
Neuroscientist and biotech entrepreneur who pioneered whole-brain mapping of drug action. Invented Theracast's platform and led the discovery of its lead drug combinations.
Jeffrey A. Lieberman, M.D.
Columbia University psychiatrist who helped shape modern psychiatric treatment — led the landmark CATIE trial and served as President of the American Psychiatric Association.
Run your compounds on the platform.
Five pharmaceutical companies have commissioned pilot programs — independent, commercial validation of whole-brain signatures for their own pipelines. We partner selectively on discovery and translational programs in CNS.
Start a conversation